BioXcel Therapeutics, Inc. (NASDAQ:BTAI – Get Rating) has earned a consensus recommendation of “Moderate Buy” from the eight brokerages that are presently covering the company, MarketBeat Ratings reports. Two investment analysts have rated the stock with a hold recommendation and five have issued a buy recommendation on the company. The average twelve-month price target among […]
DAVENPORT & Co LLC raised its position in BioXcel Therapeutics, Inc. (NASDAQ:BTAI – Get Rating) by 44.7% in the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 157,105 shares of the company’s stock after acquiring an additional 48,560 shares during the period. […]
BioXcel Therapeutics (NASDAQ:BTAI – Get Rating) had its target price reduced by HC Wainwright from $79.00 to $66.00 in a research report report published on Tuesday morning, The Fly reports. They currently have a buy rating on the stock. HC Wainwright also issued estimates for BioXcel Therapeutics’ Q1 2023 earnings at ($1.81) EPS, Q2 2023 […]
Hennion & Walsh Asset Management Inc. raised its position in BioXcel Therapeutics, Inc. (NASDAQ:BTAI – Get Rating) by 14.5% during the 4th quarter, HoldingsChannel.com reports. The institutional investor owned 39,185 shares of the company’s stock after acquiring an additional 4,954 shares during the period. Hennion & Walsh Asset Management Inc.’s holdings in BioXcel Therapeutics were […]
Operator: Good morning, and welcome to the BioXcel Therapeutics Fourth Quarter and Full Year 2022 Financial Results Conference Call. At this time, all participants are in a listen-only mode.